Increase/Decrease in Cash: The total change in cash for the company over the given period.
NovaBridge Biosciences (NBP) had Increase/Decrease in Cash of $159.80M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$232.78M |
|
$0.15M |
|
$44.63M |
|
$277.41M |
|
$16.09M |
|
-- |
|
$2.40M |
|
$18.50M |
|
$258.92M |
|
$258.92M |
|
$258.92M |
|
115.29M |
|
| Cash Flow Statement Financials | |
$-6.00M |
|
$104.97M |
|
$60.75M |
|
$68.26M |
|
$228.06M |
|
|
Increase/Decrease in Cash |
$159.80M |
$2.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|